at different concentrations ranging from 7.0-70,000 mlU/ml, no significant changes in [Ca2+]i were noted during the observation period of 10 min. Also, no significant increase in [Ca2+]i was observed by FMLP at 100 nM Although not shown, changes in the [Ca24-]! levels of SMCs by ionomycin-stimulation were noted as in the case of ECs, but such changes were absent with FMLP and EPO. No morphological changes of ECs or SMCs were observed following the addition of EPO (10,000 mlU/ml). As a cause of rhEPO-induced hypertension, Heidenreich et al. [4] suggested a direct vasopressor effect of rhEPO based on the results showing that isolated rat renal resistance vessels contract without time delay with the addition of rhEPO at concentrations ranging form 10,000 to 20,000 mlU/ml. They also described that this contractile response was not abrogated after the enzymatic removal of the ECs, but disappeared in the absence of extracellular Ca2+, suggesting involvement of the intracellular Ca-mediated pathway of the vascular SMCs. Tepel et al. [7] reported that changes in the [Ca2+]i levels of platelets by rhEPO were significantly greater in genetically hypertensive rats than in normotensive Wistar Kyoto rats, suggesting that genetic differences influence the responsiveness to rhEPO. An increase in the [Ca2+]i level of the erythroid precursor cells was observed after stimulation by rhEPO [8] , in which response the receptor for rhEPO probably played a role. Although high-and/or low-affinity receptors for rhEPO have been demonstrated on the surface of erythroids and megaka-ryocytes [9] , only one report has described low-affinity receptors in ECs [10], and none has described them in SMCs. The fact that the receptor for FMLP is limited to phagocytic cells, may account for the lack of response to EPO in our own experiment. In contrast to the results of Heidenreich et al. [4] and Tepel et al. [7] , the present results seem to be consistent with those of Pagel et al. [11] and Bund et al. [12] , both of which dispute a direct vasopressor effect of erythropoietin. At least two possibilities may explain this disagreement regarding the vascular effect of rhEPO. First, the rhEPO dosages used by Heidenreich et al. [4] and Tepel et al. [7] were much greater (10,000-250,000 mlU/ml) than our experimental dosage and physiological levels. Physiological plasma erythropoietin levels range from 10 to 20 mlU/ml [9] . Even when the plasma rhEPO levels reached a peak value of about 1,000-2,300 mlU/ml just after the intravenous injection of 3,000-6,000 U rhEPO, no immediate rise in blood pressures was reported. The plasma level of injected rhEPO rapidly reaches an undetect-able level within 48 h with a half-life of 5-7 h in hemodialysis patients [13] . There seems to be a great gap between the plasma rhEPO levels in hemodialysis patients and in those in vitro experiments affirming a vasopressor effect of rhEPO. Differences in platelet [Ca2+]i levels were not reported to correlate with those in mean blood pressure of dialysis patients [14] . Second, according to Tepel et al. [7] , genetic differences and/or the hypertensive state may influence [Ca2+]i responsiveness of platelets to rhEPO, with this point requiring further study. Although a special mechanism limited to the uremic environment cannot be ruled out, we were not able to find an in vitro direct effect of EPO on [Ca2+]i levels of the vascular cell lines. The calcium-mediated pathway of ECs and SMCs seems unlikely to be associated with rhEPO-induced hypertension.
